|
|
||||||||
The Journal of Immunology, Vol 151, Issue 10 5145-5153, Copyright © 1993 by American Association of Immunologists
ARTICLES |
TA Braciak, SK Mittal, FL Graham, CD Richards and J Gauldie
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
The majority of biologic functions assigned to cytokines have been characterized by in vitro assay systems which may not necessarily reflect cytokine roles in vivo. Recently, recombinant virus approaches have allowed tissue-specific expression of foreign gene products in experimental animal models. We have constructed recombinant human type 5 adenoviruses, deficient in the E3 region of the genome, with incorporated rodent IL-6 cDNA that express significant levels of biologically active IL-6 on infection both in vitro and in vivo. After i.p. injection, the liver, spleen, and peritoneum appear to be primary sites of expression, whereas the lung and bronchus are the main sites of expression after intratracheal instillation. Injection i.p. of BALB/c mice with the murine rIL-6 virus causes an increase in serum levels of bioactive IL-6 for up to 6 days post-infection, whereas similar changes are not seen in animals infected with control viruses. Coincident with enhanced plasma levels of IL-6, we detect raised serum levels of hepatic-derived acute phase proteins. Associated with the expression of IL-6 in the liver and spleen, at 7 days we note a fourfold splenomegaly with expansion of B and T cell compartments, as well as the presence of lymphoid aggregates in the liver. These morphologic changes had resolved by 16 days. Our findings demonstrate that recombinant human type 5 adenoviruses expressing cDNA for various cytokines could be used as a transient pseudo-transgenic animal model to investigate the biologic function of cytokines in vivo.
This article has been cited by other articles:
![]() |
I. Sonderegger, G. Iezzi, R. Maier, N. Schmitz, M. Kurrer, and M. Kopf GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival J. Exp. Med., September 29, 2008; 205(10): 2281 - 2294. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Raja Gabaglia, Y. Diaz de Durana, F. L. Graham, J. Gauldie, E. E. Sercarz, and T. A. Braciak Attenuation of the Glucocorticoid Response during Ad5IL-12 Adenovirus Vector Treatment Enhances Natural Killer Cell-Mediated Killing of MHC Class I-Negative LNCaP Prostate Tumors Cancer Res., March 1, 2007; 67(5): 2290 - 2297. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Vallance, N. Radojevic, C. M. Hogaboam, Y. Deng, J. Gauldie, and S. M. Collins IL-4 gene transfer to the small bowel serosa leads to intestinal inflammation and smooth muscle hyperresponsiveness Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G385 - G394. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakamura, T. Kouro, P. W. Kincade, A. Malykhin, K. Maeda, and K. M. Coggeshall Src Homology 2-containing 5-Inositol Phosphatase (SHIP) Suppresses an Early Stage of Lymphoid Cell Development through Elevated Interleukin-6 Production by Myeloid Cells in Bone Marrow J. Exp. Med., January 20, 2004; 199(2): 243 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. KOLB, M. INMAN, P. J. MARGETTS, T. GALT, and J. GAULDIE Budesonide Enhances Repeated Gene Transfer and Expression in the Lung with Adenoviral Vectors Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 866 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Morrison, D. L. Foss, and M. P. Murtaugh Interleukin-10 Gene Therapy-Mediated Amelioration of Bacterial Pneumonia Infect. Immun., August 1, 2000; 68(8): 4752 - 4758. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Gabaglia, B. Pedersen, M. Hitt, N. Burdin, E. E. Sercarz, F. L. Graham, J. Gauldie, and T. A. Braciak A Single Intramuscular Injection with an Adenovirus- Expressing IL-12 Protects BALB/c Mice Against Leishmania major Infection, While Treatment with an IL-4-Expressing Vector Increases Disease Susceptibility in B10.D2 Mice J. Immunol., January 15, 1999; 162(2): 753 - 760. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |